Literature DB >> 2584052

Antitumor effect of recombinant human lymphotoxin on a tumor line of human malignant glioma.

T Mikami, K Kurisu, K Kiya, K Mukada, K Kawamoto, T Hotta, T Uozumi.   

Abstract

We examined the antitumor effect of recombinant human lymphotoxin (rHuLT) on a xenotransplantable human malignant glioma line. Tumor-bearing nude mice were treated with rHuLT for three weeks following four schedules: intratumoral injection of rHuLT 20,000 units once a week, twice a week, intravenous injection once a week and twice a week. The inhibition rate of tumor growth was 98.8%, 99.1%, 92.1% and 98.8%, respectively. Histologically, necrotic lesions were observed in the tumors of all treated mice. Thrombo-obstructive changes of tumor vessels were also seen in the tumors of mice after intravenous injection of rHuLT. None of the mice died as a result of this treatment in spite of significant body weight loss. These results indicate that rHuLT has a strong antitumor effect on a xenotransplantable human malignant glioma line.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2584052

Source DB:  PubMed          Journal:  Hiroshima J Med Sci        ISSN: 0018-2052


  3 in total

1.  Growth inhibition of subcutaneously transplanted human glioma by transfection-induced tumor necrosis factor-alpha and augmentation of the effect by gamma-interferon.

Authors:  K Harada; J Yoshida; M Mizuno; K Sugita; K Kurisu; T Uozumi
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

2.  Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.

Authors:  Daxa M Patel; Paul M Foreman; L Burt Nabors; Kristen O Riley; G Yancey Gillespie; James M Markert
Journal:  Hum Gene Ther Clin Dev       Date:  2016-06       Impact factor: 5.032

3.  Tumour growth inhibition in mice by glycosylated recombinant human lymphotoxin: analysis of tumour-regional mononuclear cells involved with its action.

Authors:  I Funahashi; H Watanabe; T Abo; K Indo; H Miyaji
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.